Table of Contents Table of Contents
Previous Page  213 / 916 Next Page
Show Menu
Previous Page 213 / 916 Next Page
Page Background

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S170–S237



Prior studies have indicated that both high and low

school achievement are associated with development of bipolar

disorder (BD). We believe that the latter association may be due

to the confounding effect of family history of mental disorder.


To further investigate the association between school

achievement and subsequent development of BD by adding adjust-

ment for family history of mental disorder.


We are conducting a historical prospective cohort study

based on data from nationwide Danish registers. The cohort con-

sists of all individuals born in Denmark 1986–97 of Danish-born

parents, who were alive and living in Denmark at age 16 years, and

who have completed final examinations in 9th grade between 2002

and 2014 (


= 578,247). The cohort members will be followed until

death, emigration, development of bipolar disorder, or end of study,

whichever comes first. Hazard rate ratios for bipolar disorderwill be

calculated in a Cox model using the


-score for examination grades

as unit of exposure. The regression analyses will be adjusted for a

series of potential confounders including family history of mental



We expect to find a positive association between high

school achievement and development of BD. In contrast, we expect

to demonstrate that the association between low school achieve-

ment and BD detected in prior studies is due to confounding by

family history of mental disorder. The results will be shown at the



By further testing the potential link between emi-

nence and BD, we hope to contribute to amore balanced perception

of BD.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Emotional deficits in remitted bipolar

and schizoaffective patients

R.S. Romosan

, A.M

. Romosan , L.M. Ienciu , L. Dehelean ,

A.C. Bredicean

“Victor Babes” University of Medicine and Pharmacy, Neuroscience,

Timisoara, Romania

Corresponding author.


Both bipolar and schizoaffective patients have defi-

cient social skills persisting even during the remission of the clinical

symptoms. These deficitsmay represent impediments for the social

reintegration and recovery of these patients.


The purpose of the study was to assess and compare

emotion recognition abilities of schizoaffective and bipolar patients

during remission.


The study was conducted between 2014 and 2016

on remitted outpatients, diagnosed with either bipolar disorder



= 38) or schizoaffective disorder (


= 32), according to ICD 10

criteria, and a healthy control group (


= 65). In order to evalu-

ate patients’ ability of understanding the emotional expressions of

other people, we used the revised version of the “Reading the Mind

in the Eyes” test (“Eyes test”).


The patient group consisted of 41 (58.6%) women and

29 (41.4%) men, with a mean age of 43.57 years (SD = 10.56). The

control group was comprised of 25 males (38.5%) and 40 females

(61.5%), with a mean age of 42.03 years (SD = 11.07). We found

statistically significant differences (


= 0.003) between the patient

groups and the control group regarding emotion recognition abil-

ities (poorer emotion recognition skills than the control group in

both bipolar and schizoaffective patients). Patients with schizoaf-

fective disorder gave significantly more incorrect answers in the

“Eyes test” than bipolar patients (


= 0.015). Although not statisti-

cally significant, women had better emotion recognition abilities

than men, both in the patient sample and the control group.


Schizoaffective patients havemore severe emotional

deficits than bipolar patients during euthymic periods.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Lurasidone adjunctive to lithium or

valproate for prevention of recurrence

in patients with bipolar I disorder

J. Calabrese

1 , A. P


2 ,

, J. C


2 , Y. M


2 , A.




Case Western Reserve University, University Hospitals Case Medical

Center, Cleveland, USA


Sunovion Pharmaceuticals Inc., Medical Affairs, Fort Lee, USA

Corresponding author.


Information is not available on the maintenance

efficacy of lurasidone in bipolar disorder.


To evaluate the recurrence prevention efficacy of

lurasidone plus lithium (Li) or valproate (VPA) for the maintenance

treatment of bipolar disorder.


Patients with bipolar I disorder received up to 20 weeks

of open-label lurasidone (20–80mg/d) plus Li or VPA. Patients

who achieved consistent clinical stability were randomized to

28weeks of double-blind treatment with lurasidone (20–80mg/d)

or placebo, plus Li or VPA.


A total of 496 patients met stabilization criteria and were

randomized to adjunctive lurasidone vs. placebo. Fewer patients

in the lurasidone group had recurrence of any mood episode com-

paredwith the placebo group, with a hazard ratio of 0.71 (


= 0.078).

In pre-planned secondary analyses, recurrence rates were sig-

nificantly lower for the lurasidone group treated with a modal

open-label dose of 80mg/d (hazard ratio [HR], 0.35;


= 0.020);

when patients presented with an index episode of depression

(HR = 0.57;


= 0.039); and when outcome was time-to-all-cause

discontinuation (HR = 0.72;


= 0.034), or time-to-recurrence based

on symptom severity criteria (HR = 0.53;


= 0.025).


In patients stabilized on lurasidone plus Li or VPA,

continued treatmentwas associatedwithnon-significant reduction

in risk of recurrence of any mood disorder (primary). Consistent

with dose-response effects observed during acute treatment of

bipolar depression, risk of recurrence on lurasidone was signifi-

cantly reduced after open-label treatment with the 80mg/d dose,

and in the 20–80mg/d dose in patients presenting with an index

episode of depression. NCT01358357.

Sponsored by Sunovion Pharmaceuticals Inc.

Disclosure of interest

Drs. Pikalov, Cucchiaro, Mao, and Loebel

are employees of Sunovion Pharmaceuticals IncDr. Calabrese has

received research support from Abbott, AstraZeneca, Bristol-Myers

Squibb, Cephalon, Cleveland Foundation, Eli Lilly, GlaxoSmithKline,

Janssen, Lundbeck, NARSAD, Repligen, Stanley Medical Research

Institute, Takeda, and Wyeth. Dr. Calabrese consulted to or served

on advisory boards of Abbott, AstraZeneca, Bristol-Myers Squibb,

Cephalon, Dainippon Sumitomo, Elan, EPI-Q, Inc., Forest, France

Foundation, GlaxoSmithKline, Hoffman LaRoche, Janssen, Johnson

and Johnson, Lundbeck, Merck, Neurosearch, OrthoMcNeil, Otsuka,

Pfizer, Repligen, Servier, Solvay, Sunovion, Supernus, Synosia,

Takeda, Teva, and Wyeth. Dr. Calabrese has provided CME lectures

supported by AstraZeneca, Bristol-Myers Squibb, France Foun-

dation, GlaxoSmithKline, Janssen, Johnson and Johnson, Merck,

Sanofi-Aventis, Schering-Plough, Pfizer, Solvay, Sunovion, and